Diabetic ketoacidosis: SGLT2 inhibitors were associated with a significantly increased risk of DKA compared with placebo (RR = 2.24, 95% CI = 1.45-3.46). The gene discussed is SLC5A2; the disease is diabetic ketoacidosis.